Wealth Enhancement Advisory Services’s Royalty Pharma RPRX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.88M	Buy	179,888 +141,175	+365%	+$7.35M	0.02%	677
2026 Q1	$1.88M	Sell	38,713 -150,333	-80%	-$6.58M	﹤0.01%	1424
2025 Q4	$7.68M	Buy	189,046 +165,451	+701%	+$6.31M	0.01%	804
2025 Q3	$852K	Buy	23,595 +3,394	+17%	+$123K	﹤0.01%	1969
2025 Q2	$735K	Buy	20,201 +3,841	+23%	+$127K	﹤0.01%	1931
2025 Q1	$509K	Buy	16,360 +6,700	+69%	+$212K	﹤0.01%	2059
2024 Q4	$246K	Buy	+9,660	New	+$256K	﹤0.01%	2538
2024 Q2	–	Sell	-7,197	Closed	-$219K	–	2690
2024 Q1	$219K	Buy	+7,197	New	+$212K	﹤0.01%	2132

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wealth Enhancement Advisory Services's RPRX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Royalty Pharma (RPRX) stake by 365% in Q2 2026, buying an estimated $7.35M and bringing the position to 179,888 shares worth $9.88M. The position accounts for 0.02% of the portfolio, ranked #677.

Wealth Enhancement Advisory Services first reported a position in RPRX in Q1 2024 and has held it in 8 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Wealth Enhancement Advisory Services held 179,888 shares of Royalty Pharma worth $9.88M as of Q2 2026.
Wealth Enhancement Advisory Services bought 141,175 Royalty Pharma shares in Q2 2026, an estimated $7.35M.
Royalty Pharma made up 0.02% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #677 holding.
Wealth Enhancement Advisory Services first reported a position in Royalty Pharma in Q1 2024 and has held it in 8 quarters since.
646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.